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Summary. — The aim of this work was to evaluate proton therapy effectiveness
in combination with a molecule SRC protein inhibitor for glioblastoma multiforme
treatment. The role of this novel compound, Si306, is to interfere with glioblastoma
carcinogenesis and progression, creating a radiosensitivity condition. The experi-
ments were performed on U87 human glioblastoma multiforme cell line. Molecule
concentrations of 10 μM and 20 μM were tested in combination with proton ir-
radiation doses of 2, 4, 10 and 21 Gy. Cell survival evaluation was performed by
clonogenic assay. The results showed that Si306 increases the efficacy of proton
therapy reducing the surviving cells fraction significantly compared to treatment
with protons only. These studies will support the preclinical phase realization, in
order to evaluate proton therapy effects and molecularly targeted drug combined
treatments.
1. – Introduction
Glioblastoma multiforme (GBM) belongs to the group of diffuse astrocytic and oligo-
dendroglial tumor of the gliomas family. The highest grade (IV grade) is assigned to
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GBM, according to the World Health Organization (WHO) classification based on ma-
lignancy histological criteria, proliferation index, aggressiveness, response to therapy and
life expectancy [1].
The current standard treatment establishes conventional radiotherapy (RT) of 2 Gy
for 30 fractions with the alkylating agent temozolomide (TMZ) both concomitantly and
RT adjuvant [2]. At present, these treatments are not curative and the median overall
survival (OS) is only 14–15 months after diagnosis [3]. Furthermore, radionecrosis and
neurocognitive dysfunctions are the main causes of late tissue toxicities of the surrounding
organs [4]. Proton therapy (PT), unlike conventional RT, shows physical characteristics
which contribute to an overall improved risk-benefit profile in radiotherapy. The reverse
depth dose profile of protons allows to hit the cancerous target sparing healthy tissues [5].
For this reason, PT can avoid side effects and increase median OS by means of protocols
with dose escalation such as hyperfractionated treatments [6]. Actually, although the
demonstration of an overall improved risk-benefit profile and an extension of the OS
emerging from clinical trials, some aspects still need to be clarified. In particular, the
excessive radiation necrosis and radioresistance phenomena are key features of GBM
under investigation [7]. To date, the cellular pathways involved in radioresistance are
not fully known. SRC protein non-receptor kinase is one of the main molecular targets
involved in GBM radioresistance. In fact, SRC is a key factor which contributes to
regulate the main hallmarks of GBM, such as cell morphology, adhesion, migration,
invasion, proliferation, differentiation and cell survival [8]. For this reason, the SRC
inhibitor compound Si306, has been designed to block the SRC protein activity, with
the aim to enhance PT effectiveness and to reduce radioresistance. Computational and
modelling analysis have revealed that Si306, can specifically bind the ATP site of the SRC
protein making it inactive [9]. In particular, in previous studies it has been demonstrated
that Si306 determines a significant reduction in glioblastoma cell proliferation, migration
and an enhancement in growth inhibition. Antiproliferative effect of Si306, has been
tested in association with X-ray both in vitro and in vivo. It has been observed that
the combination effect of Si306, and RT reduced significantly colony numbers in vitro
in low-density growth assay compared to the cells treated with only RT. For the in
vivo studies the combination treatment determined a significant reduction of the tumour
growth compared to untreated group [10]. The aim of this preliminary study was to
evaluate PT effects in combination with the compound Si306. In our study we tested
two concentrations of Si306, 10μM and 20 μM, combined with PT delivering four doses, 2,
4, 10 and 21 Gy, on U87 human glioblastoma cell line. Our results show an enhancement
effect on cell killing by Si306 with proton beam.
2. – Materials and methods
2.1. Cell culture. – The U87 MG human glioblastoma cell line was purchased from
American Type Culture Collection (ATCC, Manassas, VA, USA). The cell line was cul-
tured according to ATCC, in Basal Medium Eagle (BME) supplemented with 10% FBS,
1% penicillin/streptomycin, 1% glutamine, 1% non-essential amino acids and sodium
pyruvate. Cells were maintained in an exponentially growing culture condition in incu-
bator at 37 ◦C in a humidified atmosphere (95% air and 5% CO2) and were routinely
sub cultured in 25 cm2 (T25) standard tissue culture flasks.
2.2. Si306 treatment . – The compound Si306 was kindly provided by Lead Discovery
Siena (Siena, Italy). It was dissolved in Dimethylsulfoxid (DMSO, Sigma-Aldrich) with
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final concentrations not exceeding 0.5% of DMSO. According to IC50 (drug concentration
that determined the 50% of growth inhibition) previously calculated [10], U87 cells were
pretreated with Si306 concentrations of 10μM and 20μM for 24 h. After incubation
time, the medium was removed, cells were rinsed two times with phosphate buffered
saline (PBS) and fresh medium was added before the irradiations with a proton beam.
2.3. Proton irradiation. – The proton beam irradiation was performed at the CATANA
(Centro di Adroterapia ed Applicazioni Nucleari Avanzate) facility of INFN-LNS (Cata-
nia, Italy) [11]. It is the first Italian proton therapy facility and it has been in operation
since 2002. Here, using 62 MeV of proton beams accelerated by a cyclotron supercon-
ducting, patients affected by ocular melanoma are treated. The beamline is composed of
several passive elements optimized for the clinical application: scattering foils to spread
the beam laterally, collimators to define the beam profile in accordance to the tumor
shape and monitor chambers to measure the dose delivered. In order to irradiate the
entire T25 flask, a motorized system for biological samples irradiation was used. Ra-
diochromic film detectors were adopted to check lateral dose distribution before each
irradiation. The dosimetric system was calibrated under reference conditions according
to the International Atomic Energy Agency Technical Reports Series No. 398 “Absorbed
Dose Determination in External Beam Radiotherapy” [12,13]. For combined treatments
with 10μM and 20μM of Si306, U87 cell line irradiations were carried out using four dose
values of 2, 4, 10 and 21 Gy. The same irradiation treatments were performed without
the compound Si306, including also dose values of 1, 3 and 6 Gy in order to obtain a
clonogenic survival curve as control. Cell irradiations were conducted placing the cell at
the middle spread-out Bragg peak, to simulate a clinical condition, with a dose rate of
15 Gy/min.
2.4. Clonogenic assay . – Two days before treatments, U87 cells were seeded in T25
flasks at a density of 3 × 105/flask and maintained at subconfluence. After irradiation,
the cell survival was performed by clonogenic assay according to the protocol of Franken
et al. [14] Briefly, after irradiation, U87 cells were detached, counted by haemocytometer
and seeded in a 6-well plate in triplicate at a density of 50–2000 cells per well according
to the dose delivered to assay the surviving fraction (SF). The number of cells plated
was chosen to yield at least 50 colonies per flask. After an incubation time of 12 or
14 days, cells were fixed with 50% methanol for 20 min and stained with 0.5% crystal
violet (both from Sigma-Aldrich, St. Louis, MO, USA). Colonies with more than 50 cells
were counted as clonogenic and SF determined according to the plating efficiency (PE)
of untreated cells (control).
3. – Results
The effect of Si306 alone and in combination with PT was assessed in U87 cells. After
cell exposure with Si306 alone at concentration of 10μM and 20μM, we observed a SF
of 80% and 60%, respectively, showing a dose-response relationship. Following proton
irradiation with doses of 2, 4, 10 and 21 Gy, the SF of the U87 cells without the drug
obtained were as follows: 40%, 21%, 7% and 3%. Cell survival was further reduced after
the pre-treatment with Si306 combined with the irradiation treatment. SF obtained after
combined treatments were as follows at the same irradiation doses: 28%, 20%, 5% and
3% for the setting with 10μM of Si306; 16%; 10%, 4% and 2% for the setting with 20μM
of Si306. The results of clonogenic assays for U87 cell lines after irradiation with protons
alone and in combination with Si306 are shown in fig. 1.
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Fig. 1. – Effect of Si306 in combination with proton therapy on the human U87 glioblastoma
cell line. Bar diagrams of surviving fraction are in percentage. The data are mean±SD of three
independent experiments.
4. – Discussion
In this study, we evaluated the effect of PT combined with a novel molecule in-
hibitor of SRC on the glioblastoma cell line using clonogenic assay. The work shows
that pretreatment with the compound Si306 contribute to weak clonogenic activity of
glioblastoma cells irradiated with proton beams. In addition to the radiosensitivity eval-
uation, one of our main goals is to investigate IR-induced radioresistance at molecular
level since gene expression profiling may reflect different clinical outcomes by assuming
a significant prognostic value of gene signatures to predict a glioblastoma response to
the radiation treatment. Therefore, gene expression analyses by whole-genome cDNA
microarray are in progress in order to evaluate ionizing radiation-induced pathways that
can be modulated by Si306 activity. There are no available studies about gene signatures
proton-induced, especially in combination with targeted molecules.
From a clinical perspective, PT might be a promising treatment for patients with
GBM and the inhibition of SRC tyrosine kinase proteins is a favourable strategy to
overcome invasion, migration and other mechanisms involved in radioresistance of GBM.
Previous studies have shown that inhibition of SRC proteins reduces the expression of
vascular endothelial growth factor (VEGF) and invasive processes that can be triggered
by direct inhibitors of VEGF, such as bevacizumab or by exposure to IR itself [15-17].
Over recent years, few in vitro studies have been performed about the proton effects in
association with molecular targeted drugs for GBM treatment. Among the studies with
particle therapies, most of the information is related to the evaluation of the effect of
high-LET particles, such as carbon ions combined with TMZ or other chemotherapeutic
agents [18-20]. Although a greater radiobiological efficacy of carbon ions has been shown
for glioblastoma cell lines compared to photon irradiation, we encourage to implement
studies that guide towards a new clinical trial for PT. One of the main reasons is the
limited availability of dedicated facilities for carbon ion therapy compared to PT centres:
more than 100,000 patients have been already treated in 50 centres for cancer treatment
with protons. Carbon ion centres instead are located in few countries, since only two of
them are in Europe: Heidelberg Ion-Beam Therapy Centre (HIT) in Heidelberg, Germany
and Centro Nazionale di Adroterapia Oncologica (CNAO) in Pavia, Italy [21,22].
This work shows for the first time the effects following the combination of proton
irradiation with a molecular targeted agent blocking SRC protein in the GBM cell line.
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Therefore, our in vitro results represent radiobiological data useful for subsequent pre-
clinical steps, as well as clinical applications, contributing to define a personalized bio-
logically driven treatment plan.
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